JOHNSON & JOHNSON (JNJ)
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
📈 **POSITIVE** • High confidence analysis (86%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business